Biotech Values

[microcapfun]

>>Avastin is seen by oncologists as a very well tolerated drug actually. If vegf-trap is less well tolerated, unless they show trap is more effective, why would it be used?<<

Another way of putting it is one can always dial down the AEs by dialing down the dose. So when someone says a drug is less well tolerated than another drug, what they are really saying is that it has a smaller therapeutic window.

Another observation is that in monotherapy, efficacy tends to trump side effects in life-threatening indications. But in such indications, lesser side effects become a more significant advantage when drugs are used in combination.

I always found it interesting that despite multiple approvals with more on the way, Avastin isn't approved as a monotherapy in ANY indication. (I think that's right.) Is there any other cancer drug which can make that claim?

I guess that could be considered a quiz question to which I don't know the answer ...

micro